The intravesical Bacillus Calmette-Guérin (BCG) vaccine has been the gold standard treatment for non-muscle invasive bladder cancer for 44 years, making it one of the most successful biotherapies to date. However, international shortages have forced the rationing of this crucial medication, negatively impacting the primary treatment of high-grade non-muscle invasive bladder cancer. By examining the history of intravesical BCG, we can gain insights into these shortages and explore future opportunities for novel immunotherapy treatments against this serious disease.
Research
M Harvey, M Perera, N Lawrentschuk, D Bolton, G JackCritical shortage in BCG immunotherapy: How did we get here and where will it take us?2021, In Press
M Harvey, M Perera, N Lawrentschuk, D Bolton, G Jack
Critical shortage in BCG immunotherapy: How did we get here and where will it take us?
2021, In Press
Dr. Marlon Perera
Dr. Marlon Perera is an Australian-trained, award-winning urology surgeon who specialises in robotic surgery and uro-oncology. Dr. Perera has worldwide experience, having completed a PhD (Urology) and a prized-accredited ‘Society of Urologic Oncology’ (SUO) fellowship at one of the world’s best and most prestigious cancer centres – Memorial Sloan Kettering Cancer Center in New York City. He provides comprehensive care in the treatment of prostate cancer, kidney masses and cancers, bladder cancer, kidney stones, and voiding dysfunction.